<SEC-DOCUMENT>0001157523-14-001939.txt : 20140506
<SEC-HEADER>0001157523-14-001939.hdr.sgml : 20140506
<ACCEPTANCE-DATETIME>20140506160644
ACCESSION NUMBER:		0001157523-14-001939
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20140506
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140506
DATE AS OF CHANGE:		20140506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD RESEARCH CORP
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21898
		FILM NUMBER:		14817098

	BUSINESS ADDRESS:	
		STREET 1:		225 SOUTH LAKE AVENUE
		STREET 2:		SUITE 1050
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101
		BUSINESS PHONE:		626-304-3400

	MAIL ADDRESS:	
		STREET 1:		225 SOUTH LAKE AVENUE
		STREET 2:		SUITE 1050
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a50859207.htm
<DESCRIPTION>ARROWHEAD RESEARCH CORP. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2014 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 10pt; font-family: Times New Roman">
    <p style="text-align: center">
      <br>
      <br>
      <font style="font-family: Times New Roman; font-size: 18pt"><b>UNITED
      STATES</b></font><b><font style="font-family: Times New Roman; font-size: 18pt"><br style="font-size: 18pt; font-family: Times New Roman"></font><font style="font-family: Times New Roman; font-size: 18pt">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-family: Times New Roman; font-size: 12pt"><b>WASHINGTON,
      D.C. 20549</b></font><br><br><font style="font-family: Times New Roman; font-size: 18pt"><b>FORM
      8-K</b></font><br><br><font style="font-family: Times New Roman; font-size: 12pt"><b>CURRENT
      REPORT</b></font><br><br><font style="font-family: Times New Roman; font-size: 12pt"><b>PURSUANT
      TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></font><br><br><font style="font-family: Times New Roman; font-size: 10pt">Date
      of Report (Date of earliest event reported): May 6, 2014</font><font style="font-family: Times New Roman; font-size: 10pt"><br style="font-size: 10pt; font-family: Times New Roman"></font><br><font style="font-family: Times New Roman; font-size: 16pt"><b>Arrowhead
      Research Corporation</b></font><br><font style="font-family: Times New Roman; font-size: 10pt">(Exact
      name of registrant as specified in its charter)</font><br><br>0-21898<br>(Commission
      File Number)<br><br>
    </p>
    <div style="text-align:center">
    <table cellspacing="0" style="margin-left:auto;margin-right:auto; width: 100%; margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman">
      <tr>
        <td style="text-align: center; padding-left: 0.0px; width: 50%" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Delaware
          </p>
        </td>
        <td style="text-align: center; padding-left: 0.0px; white-space: nowrap; width: 50%; padding-right: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            46-0408024
          </p>
        </td>
      </tr>
      <tr>
        <td style="text-align: center; padding-left: 0.0px; width: 50%" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (State or other jurisdiction of incorporation)
          </p>
        </td>
        <td style="text-align: center; padding-left: 0.0px; width: 50%" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (IRS Employer Identification No.)
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center; white-space: nowrap">

    </p>
    <p style="text-align: center; white-space: nowrap">
      225 South Lake Avenue, Suite 1050, Pasadena, CA&#160;&#160;91101<br>(Address
      of principal executive offices) (Zip Code)<br><br>Registrant's telephone
      number, including area code (626) 304-3400
    </p>
    <p style="text-align: center">

    </p>
    <p>

    </p>
    <p>
      <font style="font-family: Times New Roman; font-size: 10pt">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions:</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font>
    </p>
    <div style="width: 100%; margin-bottom: 10pt; margin-right: 0pt; margin-left: 0pt; text-indent: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p>
      <b>Item 2.02.</b> &#160;<b>Results of Operations and Financial Condition</b>
    </p>
    <p>
      On May 6, 2014, Arrowhead Research Corporation announced and commented
      on its fiscal 2014 second quarter financial results for the period ended
      March 31, 2014. A copy of the press release is furnished herewith as
      Exhibit&#160;99.1.
    </p>
    <p>
      <i>In accordance with General Instruction B.2 of Form 8-K, the
      information in this Current Report on Form 8-K, including Exhibit&#160;99.1,
      shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities
      Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise
      subject to the liabilities of that section, nor shall it be deemed
      incorporated by reference in any filing under the Securities Act of
      1933, as amended, or the Exchange Act, whether made before or after the
      date hereof, except as expressly set forth by specific reference in such
      filing to this Current Report on Form 8-K.</i>
    </p>
    <p>
      <b>Item 9.01.</b> &#160;<b>Financial Statements and Exhibits.</b>
    </p>
    <p>
      (d)&#160;Exhibits
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="width: 100%; margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman">
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 10%; border-bottom: solid black 1.0pt" valign="bottom">
          <b>Exhibit No.</b>
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 5%; padding-bottom: 2.0px" valign="bottom">
          &#160;
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 85%; border-bottom: solid black 1.0pt" valign="bottom">
          <b>Description</b>
        </td>
      </tr>
      <tr>
        <td style="width: 10%">

        </td>
        <td style="width: 5%">

        </td>
        <td style="width: 85%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 0.0px; white-space: nowrap; width: 10%; padding-right: 0.0px" valign="top">
          99.1
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 5%" valign="bottom">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 85%" valign="top">
          Press Release, dated May 6, 2014.
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="width: 100%; margin-bottom: 10pt; margin-right: 0pt; margin-left: 0pt; text-indent: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt"><b>SIGNATURES</b></font>
    </p>
    <p>
      <font style="font-family: Times New Roman; font-size: 10pt">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned thereunto duly authorized.</font>
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="width: 100%; margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman">
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 6%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Date:
          </p>
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 44%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            May 6, 2014
          </p>
        </td>
        <td style="text-align: left; padding-left: 0.0px" colspan="3" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td style="text-align: left; padding-left: 0.0px" colspan="3" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            ARROWHEAD RESEARCH CORPORATION
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="width: 5%">
          &#160;
        </td>
        <td style="width: 42%">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="width: 5%">

        </td>
        <td style="width: 42%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 6%" valign="top">

        </td>
        <td style="width: 44%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="width: 5%">

        </td>
        <td style="width: 42%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 6%; padding-bottom: 2.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 44%; padding-bottom: 2.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 3%; padding-bottom: 2.0px" valign="top">
          By:
        </td>
        <td style="width: 5%; border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 42%; border-bottom: solid black 1.0pt" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            /s/ Kenneth Myszkowski
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="width: 5%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 42%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Kenneth Myszkowski
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="width: 5%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 42%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Chief Financial Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a50855907ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2014 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 8pt; font-family: Times New Roman">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt"><b>Arrowhead
      Reports Fiscal 2014 Second Quarter Financial Results</b></font>
    </p>
    <p style="text-align: center">
      <i><font style="font-family: Times New Roman; font-size: 12pt"><b>-
      Conference Call Today at 4:30 p.m. EDT</b></font></i>
    </p>
    <p>
      PASADENA, Calif.--(BUSINESS WIRE)--May 6, 2014--Arrowhead Research
      Corporation (NASDAQ: ARWR), a biopharmaceutical company developing
      targeted RNAi therapeutics, today announced financial results for its
      fiscal 2014 second quarter ended March 31, 2014. The company is hosting
      a conference call at 4:30 p.m. EDT to discuss results. To participate in
      the conference call, please dial 855-215-6159 (toll free from the US) or
      315-625-6887 (for international callers) and enter Conference ID
      35127223. Investors may also access a live audio webcast of this
      conference call on the Company's website at <u>http://www.arrowheadresearch.com/presentations</u>.
    </p>
    <p>
      A replay of the webcast will be available approximately two hours after
      the conclusion of the call and will remain available for 90 days. An
      audio replay will also be available approximately two hours after the
      conclusion of the call and will be available for 7 days. The audio
      replay can be accessed by dialing 855-859-2056 (toll free from the US),
      or 404-537-3406 (for international callers) and entering Conference ID
      35127223.
    </p>
    <p>
      <b>Fiscal 2014 Second Quarter and Recent Company Highlights</b>
    </p>
    <ul>
      <li style="margin-bottom: 10.0px">
        Began dosing patients in a Phase 2a study of lead candidate ARC-520
        against chronic hepatitis B infection;
      </li>
      <li style="margin-bottom: 10.0px">
        Completed first dose cohort in ARC-520 Phase 2a study;
      </li>
      <li style="margin-bottom: 10.0px">
        Completed an equity financing with gross proceeds of $120 million;
      </li>
      <li style="margin-bottom: 10.0px">
        Scheduled an analyst and R&amp;D Day for June 19 in New York City to
        discuss our next clinical candidate for a rare liver indication;
      </li>
      <li style="margin-bottom: 10.0px">
        Upgraded NASDAQ listing to the Global Select Market;
      </li>
      <li style="margin-bottom: 10.0px">
        Hired additional R&amp;D staff in key areas, including manufacturing,
        toxicology, chemistry, biology, quality assurance, and regulatory and
        clinical operations to support rapid development of ARC-520 and
        additional clinical candidates.
      </li>
    </ul>
    <div style="width: 100%; margin-bottom: 10pt; margin-right: 0pt; margin-left: 0pt; text-indent: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>Selected Fiscal 2014 Second Quarter Financial Results</b>
    </p>
    <p>
      Net loss attributable to Arrowhead for the quarter was $13.9 million, or
      $0.31 per share based on 44.3 million weighted average shares
      outstanding. This compares with a net loss attributable to Arrowhead of
      $6.8 million, or $0.41 per share based on 16.5 million weighted average
      shares outstanding, for the quarter ended March 31, 2013.
    </p>
    <p>
      Total operating expenses for the quarter were $11.3 million, compared to
      $5.4 million for the quarter ended March 31, 2013. Research and
      development related expenses were $5.2 million and $1.3 million for
      general and administrative expenses.
    </p>
    <p>
      Net cash used in operating activities for the first six months of fiscal
      2014 was $14.7 million, compared with $8.3 million in the prior year
      period.
    </p>
    <p>
      The company&#8217;s cash and investments of cash were $194.7 million at March
      31, 2014, compared to $29.8 million at September 30, 2013. The increase
      in the cash balance reflects financings completed in February and
      October, plus cash inflow from exercise of warrants and stock options of
      $8 million.
    </p>
    <p>
      Common shares outstanding at March 31, 2014, were 51.9 million, and 57.5
      million assuming conversion of preferred stock outstanding.
    </p>
    <p>
      <b>About ARC-520</b>
    </p>
    <p>
      Arrowhead&#8217;s RNAi-based candidate ARC-520 is designed to treat chronic
      HBV infection by reducing the expression and release of new viral
      particles and key viral proteins. The goal is to achieve a functional
      cure, which is an immune clearant state characterized by hepatitis B
      s-antigen negative serum with or without sero-conversion. The siRNAs in
      ARC-520 intervene at the mRNA level, upstream of where nucleotide and
      nucleoside analogues act. In transient and transgenic mouse models of
      HBV infection, a single co-injection of Arrowhead&#8217;s DPC delivery vehicle
      with cholesterol-conjugated siRNA targeting HBV sequences resulted in
      multi-log knockdown of HBV RNA, proteins and viral DNA with long
      duration of effect. Arrowhead has completed enrollment in a Phase 1
      single ascending dose study in normal volunteers. The company is
      conducting a single dose Phase 2a study in chronic HBV patients, which
      it expects to follow with a multi-dose, multi-national Phase 2b study.
      Approximately 350 million people worldwide are chronically infected with
      the hepatitis B virus. Chronic HBV infection can lead to cirrhosis of
      the liver and is responsible for 80% of primary liver cancers.
    </p>
    <div style="width: 100%; margin-bottom: 10pt; margin-right: 0pt; margin-left: 0pt; text-indent: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>About Arrowhead Research Corporation</b>
    </p>
    <p>
      Arrowhead Research Corporation is a biopharmaceutical company developing
      targeted RNAi therapeutics. The company is leveraging its proprietary
      drug delivery technologies to develop targeted drugs based on the RNA
      interference mechanism that efficiently silences disease-causing genes.
      Arrowhead technologies also enable partners to create peptide-drug
      conjugates that specifically home to cell types of interest while
      sparing off-target tissues. Arrowhead&#8217;s pipeline includes clinical
      programs in chronic hepatitis B virus and partner-based programs in
      obesity and oncology.
    </p>
    <p>
      For more information please visit <u>http://www.arrowheadresearch.com</u>,
      or follow us on Twitter @ArrowRes. To be added to the Company's email
      list to receive news directly, please send an email to <u>ir@arrowres.com</u>.
    </p>
    <p>
      <b>Safe Harbor Statement under the Private Securities Litigation Reform
      Act:</b>
    </p>
    <p>
      <i>This news release contains forward-looking statements within the
      meaning of the &quot;safe harbor&quot; provisions of the Private Securities
      Litigation Reform Act of 1995. These statements are based upon our
      current expectations and speak only as of the date hereof. Our actual
      results may differ materially and adversely from those expressed in any
      forward-looking statements as a result of various factors and
      uncertainties, including our ability to finance our operations, the
      future success of our scientific studies, our ability to successfully
      develop drug candidates, the timing for starting and completing clinical
      trials, rapid technological change in our markets, and the enforcement
      of our intellectual property rights. Arrowhead Research Corporation's
      most recent Annual Report on Form 10-K and subsequent Quarterly Reports
      on Form 10-Q discuss some of the important risk factors that may affect
      our business, results of operations and financial condition. We assume
      no obligation to update or revise forward-looking statements to reflect
      new events or circumstances.</i>
    </p>
    <p>
      CONTACT:<br>Arrowhead Research Corporation<br>Vince Anzalone, CFA<br>626-304-3400<br><u>ir@arrowres.com</u><br>or<br><b>Investor
      Relations:</b><br>The Trout Group<br>Lauren Glaser<br>646-378-2972<br><u>ir@arrowres.com</u><br>or<br><b>Media:</b><br>Russo
      Partners<br>Martina Schwarzkopf, Ph.D.<br>212-845-4292<br><u>martina.schwarzkopf@russopartnersllc.com</u>
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
